v3.26.3
Overview and Basis of Presentation (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2021
Aug. 31, 2024
Sep. 30, 2026
Jun. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Disposal Group, Including Discontinued Operations [Line Items]              
Royalty income from gain on sale of oncology business     $ 2,969   $ 0 $ 2,969 $ 0
Cash, cash equivalents, and marketable securities     907,000     907,000  
Contingent Payments and Royalty Rights | Vorasidenib              
Disposal Group, Including Discontinued Operations [Line Items]              
Sale of royalty interests, percentage sold   100.00%          
Milestone payment for achievement of specified ex-U.S. commercial milestone event   $ 1,000,000          
Royalty percent for sales over $1 billion (as a percent)   12.00%          
Royalty income from gain on sale of oncology business     $ 3,000     $ 3,000  
Percentage of royalty rights retained   3.00%          
Oscotec Inc.              
Disposal Group, Including Discontinued Operations [Line Items]              
Upfront payment       $ 25,000      
Contingent consideration       $ 140,000      
Discontinued Operations, Disposed of by Sale | Contingent Payments and Royalty Rights | United States | Agios Oncology Business              
Disposal Group, Including Discontinued Operations [Line Items]              
Contingent royalty payment 15.00%